Enzon to Present at BMO Capital Markets Focus on Healthcare Conference.BRIDGEWATER Bridgewater, town (1990 pop. 21,249), Plymouth co., E Mass.; inc. 1656. Manufacturing includes shoes and metal products. Its iron foundry industry dates from colonial times. Bridgewater State College and a state prison are there. , N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Jeffrey H. Buchalter, Enzon's chairman and chief executive officer, will present at the BMO BMO Bank of Montreal (Canada) BMO Before Market Open BMO Biometrics Management Office BMO Ballistic Missile Office BMO British Mathematical Olympiad BMO Balkan Mathematical Olympiad BMO Business Management Office Capital Markets Focus on Healthcare Conference, which is being held December December: see month. 4-5 in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Enzon's presentation will take place at 11:00 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy on Tuesday, December 4, 2007. The presentation will be webcast. Interested parties can access the webcast information by going to the events page that is under shareholder information on Enzon's website at www.enzon.com. About Enzon Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar([R]), DepoCyt([R]), Abelcet([R]) and Adagen([R]). The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity toxicity /tox·ic·i·ty/ (tok-sis´i-te) the quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. . Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com. Forward Looking Statements All information in this press release is as of the date of this press release and Enzon does not intend to update this information. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion